Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

IMO, the Breathtec side of the business will either rival Owlstone Medical's business model or partnership at some point down the road with a better mousetrap (Yost Patent).

Owlstone Medical

The Breath Biopsy® product range allows academic, clinical, and pharmaceutical researchers to quickly discover and validate breath-based biomarkers in early detection and precision medicine research activities. The Breath Biopsy platform is a new diagnostic modality capable of detecting biomarkers of disease, and also exogenous compounds such as volatile drug metabolites. The ReCIVA Breath Sampler and new Breath Biopsy Kits ensure consistent and reliable collection of breath samples. VOC (volatile organic compound) biomarkers present in breath can be analyzed with high sensitivity and selectivity in Owlstone Medical’s Breath Biopsy Services Laboratory or a researcher’s own laboratory. Availability of Breath Biopsy kits makes breath biopsy widely accessible to clinical researchers and pharma companies including those without the in-house analytical capability for breath samples, without requiring these companies to purchase high-cost capital equipment.

https://www.genengnews.com/resources/new-products/breath-based-biomarkers/6123/

Breathtec Provides Update on FAIMS Breathalyzer Development Program University of Florida to Complete Prototype Development

...It is generally regarded within the global breath research community, that a portable, point of care breathalyzer device, that can accurately identify and quantify biomarkers in real-time, could dramatically enhance and improve the current research landscape. This advancement could possibly lead the way to regulatory approved testing.

The company’s continued support of Dr. Yost’s FAIMS research program is the result of an extensive internal review that was undertaken by the Company to identify the most cost and time effective path forward in order to achieve the goal of having an RUO device available for distribution to the research market. The Company also confirms that all collaborative research agreements with other third parties have now ended.

http://breathtecbiomedical.com/2018/11/05/breathtec-provides-update-on-faims-breathalyzer-development-program-university-of-florida-to-complete-prototype-development/

The recently announced appointment of Dr. Yost to Owlstone Medical's Advisory Board, IMO confirms Breathtec Biomedical and Owlstone Medical are on the same page moving into the future of breath based disease detection.

https://www.owlstonemedical.com/about/news/2018/oct/10/owlstone-medical-appoints-dr-richard-yost-scientif/

/////AMG